Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-07-14

Clinical Trial Update: Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase [Phase 2]

View source ↗

Summary

Phase 2 trial of LBH589 in adults with refractory chronic myeloid leukemia in chronic phase (terminated; results posted).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LBH589 (panobinostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myeloid Leukemia in Chronic Phase | Phase 2 | Status: TERMINATED | Results posted: 2021-07-14